Gapping up
In reaction to strong earnings/guidance/Dec SSS:
In reaction to strong earnings/guidance/Dec SSS:
- ZUMZ +17.1%, DPW +7.1%, RPM +3.5%, BLFS +1.7%, RECN +1.6%, CVS +1.2%, COST +1%
Other news:
- CNET +100.9% (announces strategic partnership with Jingtum Technology), COGT +40% (announce strategic alliance to combine analytics and intelligence with leading blockchain technology), SKLN +35.4% (Skyline Medical reports sale of 5 STREAMWAY Systems in Q4; 6 units have been booked for sale in January 2018), APOP +33.4% (announces breakthrough clinical results), TOPS +26.5% (extended the time charter agreements with Stena Bulk AB; total gross revenue backlog for the fixed charter period of all operating fleet stands at about $131 million), APHB +19.6% (Ampliphi Biosciences announces topline results for the first seven patients treated under its ongoing single-patient expanded access program; 'six patients, 86%, achieving treatment success' ), CCXI +18.7% (announces conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA), CLNT +11.5% (enters into exclusivity agreement with Channel Power for potential acquisition of Touch Media), DCIX +7% (Trend Discovery discloses increased passive stake), DOVA +6% (Dova Pharmaceuticals provides update on development strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia), MNTA +5.7% (Momenta Pharma and Mylan (MYL) announced the development strategy for M710, a proposed biosimilar to EYLEA injection; cos plan to initiate a pivotal clinical trial in patients in 1H18), OMF +5.1% (Apollo Global Management (APO) buying FIG stake, according to Reuters exclusive), ARCT +4.1% (Arcturus Therapeutics and CureVac enter into a broad strategic collaboration), OSTK +3.4% (CEO Byrne and Hernando de Soto enter MOU to form blockchain company focused on property rights), MCRB +3.3% (announces initial results from its Phase 1b study of SER-287), AMD +3.1% (seeing modest bounce in after hours/pre-mkt trade after company claims 'near-zero risk' to its chips), BOLD +1.9% (announces 'positive' interim data from the first dose cohort of ASPIRO in patients with X-Linked Myotubular Myopathy ), REXX +1.8% (after jumping 50% higher), NMFC +1.8% (authorizes an extension of its $50 mln share repurchase program), SAND +1.6% (reported record gold equivalent production in 2017 and the sale of US$18 million of securities of Equinox Gold ), SSW +1.3% (announces letter of intent for potential $250 mln Unsecured 5.50% Debenture and Warrant Investment from Fairfax Financial Holdings Limited), .
Analyst comments:
- DPZ +3.3% (upgraded to Outperform from Neutral at Credit Suisse; upgraded to Outperform from Perform at Oppenheimer)
- WWE +3.3% (upgraded to Outperform from Market Perform at Wells Fargo)
- WIX +2.9% (upgraded to Strong Buy at Raymond James )
- CNHI +2.7% (upgraded to Buy from Hold at Deutsche Bank)
- NUVA +2.4% (upgraded to Buy at Needham)
- HOLX +2.3% (upgraded to Buy from Neutral at BofA/Merrill)
- TEVA +2% (upgraded to Buy from Neutral at Citigroup)
- MRO +1.6% (upgraded to Buy from Neutral at BofA/Merrill)
- SRPT +1.5% (initiated with a Buy at Janney)
- FFIV +0.9% (upgraded to Outperform from Market Perform at BMO Capital)